Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

A cross-sectional, facility based study of comorbid non-communicable diseases among adults living with HIV infection in Zimbabwe.

Magodoro IM, Esterhuizen TM, Chivese T.

BMC Res Notes. 2016 Aug 2;9:379. doi: 10.1186/s13104-016-2187-z.

2.

Cardiovascular disease risk scores' relationship to subclinical cardiovascular disease among HIV-infected and HIV-uninfected men.

Monroe AK, Haberlen SA, Post WS, Palella FJ Jr, Kinsgley LA, Witt MD, Budoff M, Jacobson LP, Brown TT.

AIDS. 2016 Aug 24;30(13):2075-84. doi: 10.1097/QAD.0000000000001163.

PMID:
27203714
3.

A Comparison of the Diabetes Risk Score in HIV/AIDS Patients on Highly Active Antiretroviral Therapy (HAART) and HAART-Naïve Patients at the Limbe Regional Hospital, Cameroon.

Dimala CA, Atashili J, Mbuagbaw JC, Wilfred A, Monekosso GL.

PLoS One. 2016 May 19;11(5):e0155560. doi: 10.1371/journal.pone.0155560. eCollection 2016.

4.

Lower Plasma Zinc Levels in Hyperglycemic People Living with HIV in the MASH cohort.

Sneij A, Campa A, Martinez SS, Stewart T, Baum M.

J AIDS Clin Res. 2016 Feb;7(2). pii: 542. Epub 2016 Feb 15.

5.

Superior Glucose Tolerance and Metabolomic Profiles, Independent of Adiposity, in HIV-Infected Women Compared With Men on Antiretroviral Therapy.

Koethe JR, Jenkins CA, Petucci C, Culver J, Shepherd BE, Sterling TR.

Medicine (Baltimore). 2016 May;95(19):e3634. doi: 10.1097/MD.0000000000003634.

6.

What happens to cardiovascular system behind the undetectable level of HIV viremia?

d'Ettorre G, Ceccarelli G, Pavone P, Vittozzi P, De Girolamo G, Schietroma I, Serafino S, Giustini N, Vullo V.

AIDS Res Ther. 2016 Apr 27;13:21. doi: 10.1186/s12981-016-0105-z. eCollection 2016. Review.

7.

Oral Glucose Tolerance Testing identifies HIV+ infected women with Diabetes Mellitus (DM) not captured by standard DM definition.

Seang S, Lake JE, Tian F, Anastos K, Cohen MH, Tien PC.

J AIDS Clin Res. 2016 Feb;7(2). pii: 545. Epub 2016 Feb 20.

8.

Inflammation, immune activation, and cardiovascular disease in HIV.

Nou E, Lo J, Grinspoon SK.

AIDS. 2016 Jun 19;30(10):1495-509. doi: 10.1097/QAD.0000000000001109.

PMID:
27058351
9.

HealthMap: a cluster randomised trial of interactive health plans and self-management support to prevent coronary heart disease in people with HIV.

Dodson S, Klassen KM, McDonald K, Millard T, Osborne RH, Battersby MW, Fairley CK, Simpson JA, Lorgelly P, Tonkin A, Roney J, Slavin S, Sterjovski J, Brereton M, Lewin SR, Crooks L, Watson J, Kidd MR, Williams I, Elliott JH.

BMC Infect Dis. 2016 Mar 5;16:114. doi: 10.1186/s12879-016-1422-5.

10.

Risk Factors for Incident Diabetes in a Cohort Taking First-Line Nonnucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy.

Karamchand S, Leisegang R, Schomaker M, Maartens G, Walters L, Hislop M, Dave JA, Levitt NS, Cohen K.

Medicine (Baltimore). 2016 Mar;95(9):e2844. doi: 10.1097/MD.0000000000002844.

11.

Pathophysiology and management of cardiovascular disease in patients with HIV.

Nou E, Lo J, Hadigan C, Grinspoon SK.

Lancet Diabetes Endocrinol. 2016 Jul;4(7):598-610. doi: 10.1016/S2213-8587(15)00388-5. Epub 2016 Feb 10. Review.

PMID:
26873066
12.

Late Antiretroviral Therapy (ART) Initiation Is Associated with Long-Term Persistence of Systemic Inflammation and Metabolic Abnormalities.

Ghislain M, Bastard JP, Meyer L, Capeau J, Fellahi S, Gérard L, May T, Simon A, Vigouroux C, Goujard C; ANRS-COPANA Cohort Study Group.

PLoS One. 2015 Dec 4;10(12):e0144317. doi: 10.1371/journal.pone.0144317. eCollection 2015.

13.

Incidence and progression of coronary artery calcium in HIV-infected and HIV-uninfected men.

Kingsley LA, Deal J, Jacobson L, Budoff M, Witt M, Palella F, Calhoun B, Post WS.

AIDS. 2015 Nov 28;29(18):2427-34. doi: 10.1097/QAD.0000000000000847.

PMID:
26558542
14.

Demographical, Viro-Immunological, Clinical and Therapeutical Characteristics of HIV-Infected Patients in an "Epidemiologically Unexplored" Region of Italy (Calabria Region): the CalabrHIV Cohort.

Postorino MC, Luciani F, Mangano C, Carpentieri MS, Scerbo P, Priamo A, Berardelli G, Marino R, Vallone A, Serrao N, Pisani V, Costa C, Terremoto A, Foti G, Cosco L, Calderazzo M, Corigliano D, Scordo P, Strazzulla A, Torti C; CalabrHIV Study Group.

Mediterr J Hematol Infect Dis. 2015 Oct 8;7(1):e2015054. doi: 10.4084/MJHID.2015.054. eCollection 2015.

15.

Cardiovascular disease in human immunodeficiency virus infected patients: A true or perceived risk?

Shahbaz S, Manicardi M, Guaraldi G, Raggi P.

World J Cardiol. 2015 Oct 26;7(10):633-44. doi: 10.4330/wjc.v7.i10.633. Review.

16.

Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapy.

Pushpakom SP, Taylor C, Kolamunnage-Dona R, Spowart C, Vora J, García-Fiñana M, Kemp GJ, Whitehead J, Jaki T, Khoo S, Williamson P, Pirmohamed M.

BMJ Open. 2015 Oct 15;5(10):e009566. doi: 10.1136/bmjopen-2015-009566.

17.

Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat.

Mangili A, Falutz J, Mamputu JC, Stepanians M, Hayward B.

PLoS One. 2015 Oct 12;10(10):e0140358. doi: 10.1371/journal.pone.0140358. eCollection 2015.

18.

The metabolic and cardiovascular consequences of obesity in persons with HIV on long-term antiretroviral therapy.

Koethe JR, Grome H, Jenkins CA, Kalams SA, Sterling TR.

AIDS. 2016 Jan 2;30(1):83-91. doi: 10.1097/QAD.0000000000000893.

PMID:
26418084
19.

Metabolic abnormalities in human immunodeficiency virus patients with protease inhibitor-based therapy.

Ete T, Ranabir S, Thongam N, Ningthoujam B, Rajkumar N, Thongam B.

Indian J Sex Transm Dis. 2014 Jul-Dec;35(2):100-3. doi: 10.4103/0253-7184.142399.

20.

The new epidemic of non-communicable disease in people living with the human immunodeficiency virus.

Dawson R, Rom WN, Dheda K, Bateman ED.

Public Health Action. 2013 Mar 21;3(1):4-6. doi: 10.5588/pha.12.0048. No abstract available.

Items per page

Supplemental Content

Write to the Help Desk